Study | Study design | Prosthesis | Steroid injection | Time from injection to surgery | Deep infection rate | Superficial infection rate | Follow-up period | ||
---|---|---|---|---|---|---|---|---|---|
 |  |  |  | Injected | Control | Injected | Control | ||
Kaspar et al. | Retrospective cohort | THA | 80 mg methylprednisolone | 0.5-42.9 months | 4/40 | 0/40 | NR | NR | (9.9-86.2) months |
Papavasiliou et al. | Retrospective cohort | TKA | NR | NR | 3/54 | 0/90 | 12/54 | 10/90 | 1 year |
McIntosh et al. | Retrospective cohort | THA | 6–40 mg drug (not mentioned) | 112 ± 81 days | 3/224 | 1/224 | 11/224 | 8/224 | NR |
Sreekumar et al. | Retrospective cohort | THA | 80 mg depomedrone | 14 months | 0/68 | 1/136 | 0/68 | 1/136 | 25-33 months |
Desai et al. | Retrospective cohort | TKA | 80 mg depomedrone | 12 months | 0/90 | 0/180 | 2/90 | 5/180 | 1-6 years |
Haughton et al. | Retrospective cohort | THA | 80 mg depomedrone or 40 mg triamcinolone | NR | 4/254 | 14/1063 | 11/254 | 4/1063 | NR |
Meermans et al. | Retrospective cohort | THA | 80 mg depomedrone +5–15 mg levobupivacaine | 12 months | 1/175 | 1/175 | 5/175 | 7/175 | 12-131 months |
Croft et al. | Retrospective cohort | THA | 40 mg depomedrol +4 ml 2% xylocaine | 5.9 months | 0/48 | 0/48 | NR | NR | 1.4-54.1 months |